Rheumatology & Autoimmunity journal publishes work spanning basic, clinical and translational medical advancements across the full spectrum of rheumatology and autoimmunity.

Journal Metrics

  • 1.5CiteScore
  • 1.3Journal Impact Factor
  • 27%Acceptance rate
  • 34 days Submission to first decision
view all metrics

You can enjoy the benefits of open access at no cost to you; our article publication charges are currently waived. And now we are indexed in multiple databases, such as ESCI, Scopus and DOAJ. Your work will be even more discoverable!

Featured Information

Skip slideshow

Articles

REVIEW
Open access

Efficacy and safety of anifrolumab across organ domains of systemic lupus erythematosus: A systematic review and meta‐analysis

  •  6 July 2025

Graphical Abstract

Efficacy and safety of anifrolumab across organ domains of systemic lupus erythematosus: A systematic review and meta-analysis Issue ,

A systematic review and meta-analysis were conducted to review all clinical trial results of anifrolumab for treating systemic lupus erythematosus. Fourteen studies were included comprising 1322 patients and five studies were meta-analyzed. It was found that anifrolumab 300 mg IV led to clinical improvement across composite lupus scores, cutaneous disease, joint disease, and reduced flare rates. However, herpes zoster rates were increased. Early clinical trials on renal patients did not meet the primary endpoint but anifrolumab is under further investigation in lupus nephritis.

REVIEW
Open access

Clinical perspectives and comparisons between immunoglobulin G4‐related disease and antineutrophil cytoplasmic antibody‐associated vasculitis

  •  1 July 2025

Graphical Abstract

Clinical perspectives and comparisons between immunoglobulin G4-related disease and antineutrophil cytoplasmic antibody-associated vasculitis Issue ,

Clinical perspectives and comparisons between immunoglobulin G4-related disease and antineutrophil cytoplasmic antibody-associated vasculitis.

ISSUE INFORMATION
Open access

Issue Information

  •  18 June 2025
INSTRUCTIONS FOR AUTHORS
Open access

Instructions for Authors

  •  160-160
  •  18 June 2025
LETTER TO THE EDITOR
Open access

Novel LPIN2 mutations in Majeed syndrome induce NF-κB pathway activation

  •  13 June 2025

Graphical Abstract

Novel LPIN2 mutations in Majeed syndrome induce NF-κB pathway activation Issue ,

This study identifies novel LPIN2 mutations in Majeed syndrome that induce NF-κB pathway activation, linking defective LPIN2 function to aberrant inflammation in this rare autoinflammatory disorder.

REVIEW
Open access

Mitochondrial dynamics in autoimmune diseases

  •  29 May 2025

Graphical Abstract

Mitochondrial dynamics in autoimmune diseases Issue ,

Roles of mitochondrial dynamic imbalance in autoimmune diseases. The imbalance of mitochondrial fusion and fission is involved in the occurrence and development of autoimmune diseases, including systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, type 1 diabetes, psoriasis, and autoimmune hepatitis.

ORIGINAL ARTICLE
Open access

Predictors of systemic sclerosis patients with interstitial lung disease progression: A retrospective study

  •  20 May 2025

Graphical Abstract

Predictors of systemic sclerosis patients with interstitial lung disease progression: A retrospective study Issue ,

The final systemic sclerosis patients with interstitial lung disease (SSc-ILD) progression prediction model was composed of 6 significant risk factors: male, type 2 diabetes mellitus, pericardial effusion, anti-Ro52, hypoproteinemia, and elevated C-reactive protein. Our model demonstrated excellent prognostic utility.

LETTER TO THE EDITOR
Open access

Association of OAS1 rs1051042 polymorphism with genetic susceptibility and clinical phenotypes to systemic lupus erythematosus in a Chinese population

  •  15 May 2025

Graphical Abstract

Association of OAS1 rs1051042 polymorphism with genetic susceptibility and clinical phenotypes to systemic lupus erythematosus in a Chinese population Issue ,

OAS1 is an interferon-induced gene that has been reported to be associated with the susceptibility of some infectious diseases, but there is little data on OAS1 single nucleotide polymorphism (SNP) associated with Systemic lupus erythematosus (SLE). In this study, we evaluated the association of OAS1 rs1051042 polymorphism with the genetic susceptibility and clinical phenotypes of SLE. Our results revealed patients with CG and GG genotypes were more susceptible to SLE. The genotype CG, GG, and allele G were associated with increased genetic susceptibility of SLE. OAS1 rs1051042 polymorphism was associated with clinical manifestations of SLE including malar rash, lupus nephritis, and anti-dsDNA antibodies. The expression levels of OAS1 were more significantly increased in genotype GG than in genotype CC and CG. Our results indicate polymorphism of OAS1 rs1051042 was associated with the genetic susceptibility and specific clinical phenotypes of SLE in the Chinese population.

More articles
More articles

Latest news

Recent issues